title: The influence of CYP2C19 genetic polymorphism on the pharmacokinetics/- pharmacodynamics of proton pump inhibitor-containing Helicobacter pylori treatments.
abstract: Proton pump inhibitors (PPIs) are the most potent acid suppressants available. PPIs undergo hepatic metabolism via the CYP2C system for the isoforms CYP2C19 and CYP3A4 in particular. Genetic polymorphisms in CYP2C19 may affect the metabolism of individual PPIs to different extents. Although PPIs are highly effective as a class, differences in their pharmacokinetics, such as bioavailability and metabolism, may translate into differences in clinical outcomes. In Helicobacter pylori infection, a significantly lower eradication rate was seen in extensive metabolizers with omeprazole but no with rabeprazole.
authors.affiliation: Department of Pharmaceutical Technology, Faculty of Pharmacy, Complutense University, Madrid, Spain.
authors.forename: Dolores
authors.initials: D
authors.lastname: Serrano
authors.forename: Susana
authors.initials: S
authors.lastname: Torrado
authors.forename: Santiago
authors.initials: S
authors.lastname: Torrado-Santiago
authors.forename: Javier P
authors.initials: JP
authors.lastname: Gisbert
mesh_terms: D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics*; D065731:Cytochrome P-450 CYP2C19; D016481:Helicobacter Infections / Q000188:drug therapy / Q000235:genetics*; D016480:Helicobacter pylori; D006801:Humans; D011110:Polymorphism, Genetic; D054328:Proton Pump Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use
chemical_list: D054328:Proton Pump Inhibitors; D001189:Aryl Hydrocarbon Hydroxylases; C045793:CYP2C19 protein, human; D065731:Cytochrome P-450 CYP2C19